biostudies-literatureUnknown30(7)Colhoun HMNovo Nordisk A/SThe SELECT trial previously reported a 20% reduction in major adverse cardiovascular events with semaglutide (n = 8,803) versus placebo (n = 8,801) in patients with overweight/obesity and established cardiovascular disease, without diabetes. In the present study, we examined the effect of once-weekly semaglutide 2.4 mg on kidney outcomes in the SELECT trial. The incidence of the pre-specified main composite kidney endpoint (death from kidney disease, initiation of chronic kidney replacement therapy, onset of persistent estimated glomerular filtration rate (eGFR) < 15 ml min^-1 1.73 m^-², persistent ≥50% reduction in eGFR or onset of persistent macroalbuminuria) was lower with semaglutide (1.8%) versus placebo (2.2%): hazard ratio (HR) = 0.78; 95% confidence iNature medicine2058-2066https://www.ebi.ac.uk/biostudies/studies/S-EPMC11271413biostudies-literatureLong-term kidney outcomes of semaglutide in obesity and cardiovascular disease in the SELECT trial.PMC11271413Plutzky JDeanfield JLingvay INode KRathor NTuttle KRLincoff AMWilding JPHBrown-Frandsen KKahn SEMann JFEParkhomenko ARyden LIdorn TBrown PMColhoun HMfalseLong-term kidney outcomes of semaglutide in obesity and cardiovascular disease in the SELECT trial.The SELECT trial previously reported a 20% reduction in major adverse cardiovascular events with semaglutide (n = 8,803) versus placebo (n = 8,801) in patients with overweight/obesity and established cardiovascular disease, without diabetes. In the present study, we examined the effect of once-weekly semaglutide 2.4 mg on kidney outcomes in the SELECT trial. The incidence of the pre-specified main composite kidney endpoint (death from kidney disease, initiation of chronic kidney replacement therapy, onset of persistent estimated glomerular filtration rate (eGFR) < 15 ml min^-1 1.73 m^-², persistent ≥50% reduction in eGFR or onset of persistent macroalbuminuria) was lower with semaglutide (1.8%) versus placebo (2.2%): hazard ratio (HR) = 0.78; 95% confidence i2024-01-01T00:00:00Z2024 Jul2026-06-01T06:55:37.2Z2025-04-19T13:11:38.367ZS-EPMC112714133879665310.1038/s41591-024-03015-5